Article • Dean Baker’s Beat the Press
Fact-based, data-driven research and analysis to advance democratic debate on vital issues shaping people’s lives.
Center for Economic and Policy Research
1611 Connecticut Ave. NW
Suite 400
Washington, DC 20009
Tel: 202-293-5380
Fax: 202-588-1356
https://cepr.net
That’s what readers of this Post tidbit would like to know. The item tells readers that Teva will be granted exclusive marketing rights for three years. This means that it can sell the drug for considerably more than its free market price. That implies a transfer of tens or hundreds of millions of dollars to the executives and shareholders in Teva from the rest of us. It’s not clear why we should tax the public as a whole, or women who buy the drug to make these people richer. The Post should at least have given us a hint as to the reason.